Today we learn that a biogeneric form of Remicade, the first biogeneric monoclonal antibody, will shortly be available in Europe: Tuesday's final green light for Inflectra - which…
September is a strange month, isn't it? It's the unofficial end of summer, so we're all getting back into the swing with everyone back in the office. Yet…
Today we learn that Endo is acquiring Boca Pharmacal for $225 million: Boca Pharmacal is a specialty generics company that focuses on niche areas, commercializing and developing products…
At Lacerta Bio, we believe that business development is a process...a process with discrete steps, activities, timeframes, and deliverables. Yet many companies, fully aware of how to run…
How much does it cost to develop an approved drug? We may never know, but Matt Herper from Forbes takes an interesting approach to come up with some estimates.
Texas-based Pernix Therapeutics announced a $30 million divestment of a portfolio of generic assets to Breckenridge: Under the terms of the agreement, Breckenridge will pay…
We don't normally comment on stock activity, but the market response to the Perrigo Elan announcement caught our eye: As was pointed out in The Guardian: Perrigo, which…
According to Burrill & Company, July had the busiest week of biotech IPO activity ever, continuing a trend of heavy fundraising during 2013 so far: In all, 29…
In a surprise decision last week, the US FDA decided to approve Brisdelle, a low-dose formulation of paroxetine, for the treatment of menopausal hot flashes. This comes on…
Many people think of the BRIC countries as good domestic opportunities. But as this recent article points out, the Indian export market is growing rapidly. India's leading pharmaceutical…